<SEC-DOCUMENT>0001657312-23-000008.txt : 20230509
<SEC-HEADER>0001657312-23-000008.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509061329
ACCESSION NUMBER:		0001657312-23-000008
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230509
ITEM INFORMATION:		Results of Operations and Financial Condition
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verona Pharma plc
		CENTRAL INDEX KEY:			0001657312
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38067
		FILM NUMBER:		23899793

	BUSINESS ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
		BUSINESS PHONE:		011-44-0-2032834200

	MAIL ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vrna-20230509.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:02513115-553c-4185-be33-9e67d07cd5d7,g:7039ddd0-aa47-44f2-98f7-19a47995764e,d:1e2dc0430f3646028f457f8334a1c0cc--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrna-20230509</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY180L2ZyYWc6OTY3NDU5OWFhMDNjNDQ2MThlY2I0ZmI2MTdiMmM1NjgvdGFibGU6MzQ0MDMyOGE1M2M2NDQzZTgxNDhkYTdjNmFkN2FhMjMvdGFibGVyYW5nZTozNDQwMzI4YTUzYzY0NDNlODE0OGRhN2M2YWQ3YWEyM18wLTEtMS0xLTgwNTg5_fdd5fe7c-9cb9-4fb3-962c-ce8e155498bc">0001657312</ix:nonNumeric><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY180L2ZyYWc6OTY3NDU5OWFhMDNjNDQ2MThlY2I0ZmI2MTdiMmM1NjgvdGFibGU6MzQ0MDMyOGE1M2M2NDQzZTgxNDhkYTdjNmFkN2FhMjMvdGFibGVyYW5nZTozNDQwMzI4YTUzYzY0NDNlODE0OGRhN2M2YWQ3YWEyM18xLTEtMS0xLTgwNTg5_9b315bb9-7b75-4b14-821a-6a9058f93bc1">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrna-20230509.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-09</xbrli:startDate><xbrli:endDate>2023-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1e2dc0430f3646028f457f8334a1c0cc_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjIz_9f34f9e3-a5eb-4de5-891b-067e3cb3a98f">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8yNDA_241f75e1-4e59-48fd-a170-263ecbcf939e">May 9, 2023</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjE5_6cba8165-2591-4743-98be-9e2b02b5d188">Verona Pharma plc</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6NTkyOWI2ZDRmOThkNGM3OWIwODE2NzVmY2ZlNWNlNTEvdGFibGVyYW5nZTo1OTI5YjZkNGY5OGQ0Yzc5YjA4MTY3NWZjZmU1Y2U1MV8wLTAtMS0xLTgwNTg5_36cae265-8142-4d80-80e1-42ef12c27997">United Kingdom</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6NTkyOWI2ZDRmOThkNGM3OWIwODE2NzVmY2ZlNWNlNTEvdGFibGVyYW5nZTo1OTI5YjZkNGY5OGQ0Yzc5YjA4MTY3NWZjZmU1Y2U1MV8wLTItMS0xLTgwNTg5_e03b2fa2-1481-4d39-8640-188ea7eab964">001-39067</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6NTkyOWI2ZDRmOThkNGM3OWIwODE2NzVmY2ZlNWNlNTEvdGFibGVyYW5nZTo1OTI5YjZkNGY5OGQ0Yzc5YjA4MTY3NWZjZmU1Y2U1MV8wLTQtMS0xLTgwNTg5_e8506cbf-4c1e-4615-80ac-bd8a47d9f5a9">98-1489389</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjI0_7e93d31e-3648-4bf8-8e3f-04af62952ab0">3 More London Riverside</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjI1_15c27cde-e5d1-4bf1-81ea-d3537bda1fc0">London</ix:nonNumeric> <ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjIw_82bd4543-1b99-416e-bf46-e3647f55c1bf">SE1 2RE</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjIx_c194cbad-fdcf-419d-a7e9-8ad132900b21">United Kingdom</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+<ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:CountryRegion" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjE2_a1d3bdd9-9157-48de-bbba-e904dd679cc0">44</ix:nonNumeric> <ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjE3_2a4118a0-f3e3-44e2-9113-198a67a62bb0">203</ix:nonNumeric> <ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjIy_fc7f5bc0-989a-413c-aa0a-f6295feba2ac">283 4200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6ZmZjMDU5MDQ4OWNiNDEyOWE3NjNjMzMxNmM1NDM3ZjUvdGFibGVyYW5nZTpmZmMwNTkwNDg5Y2I0MTI5YTc2M2MzMzE2YzU0MzdmNV8wLTEtMS0xLTgwNTg5_4e79c6cb-6cad-4776-bd2f-7fb0287f028c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6MmQ1YjYxYTY2NzJiNDZlZDk1NTQ3MzNhM2NiOWU1M2EvdGFibGVyYW5nZToyZDViNjFhNjY3MmI0NmVkOTU1NDczM2EzY2I5ZTUzYV8wLTEtMS0xLTgwNTg5_98e6ee5c-b9e9-4bf5-aeef-bc4f0b175383">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6YTZlZWNmNDYxODFlNDk1MDkzNmFhNmRhZmI1N2Y0MjMvdGFibGVyYW5nZTphNmVlY2Y0NjE4MWU0OTUwOTM2YWE2ZGFmYjU3ZjQyM18wLTEtMS0xLTgwNTg5_bf5a0f0f-8130-467b-8c4a-ce544fcc3698">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6MGUwZDVjZDM3MWI4NDI1OGFhZGE0ZmQzNjEwNzdkMWMvdGFibGVyYW5nZTowZTBkNWNkMzcxYjg0MjU4YWFkYTRmZDM2MTA3N2QxY18wLTEtMS0xLTgwNTg5_9ea1823a-23fd-49ff-89b6-ef9b21f6e0b1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:&#160;</span></div><div style="margin-bottom:6pt;padding-left:6.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:33.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which <br/>registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6ZmMwYWI0OWFjYWQ3NDQ3ZTliYjRmNTU2MmFkZGNiOTAvdGFibGVyYW5nZTpmYzBhYjQ5YWNhZDc0NDdlOWJiNGY1NTYyYWRkY2I5MF8xLTAtMS0xLTgwNTg5_0356b6f9-7ee1-44bd-ba64-0d74becbde90">Ordinary shares, nominal value &#163;0.05 <br/>per share*</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6ZmMwYWI0OWFjYWQ3NDQ3ZTliYjRmNTU2MmFkZGNiOTAvdGFibGVyYW5nZTpmYzBhYjQ5YWNhZDc0NDdlOWJiNGY1NTYyYWRkY2I5MF8xLTEtMS0xLTgwNTg5_c42609b1-8d26-48df-aa12-5647b83cab07">VRNA</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6ZmMwYWI0OWFjYWQ3NDQ3ZTliYjRmNTU2MmFkZGNiOTAvdGFibGVyYW5nZTpmYzBhYjQ5YWNhZDc0NDdlOWJiNGY1NTYyYWRkY2I5MF8xLTItMS0xLTgwNTg5_8f1d0fbd-5ac8-49a2-b970-220967423686">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* The ordinary shares are represented by American Depositary Shares (each representing 8 ordinary shares), which are exempt from the operation of Section&#160;12(a)&#160;of the Securities Exchange Act of 1934, as amended, pursuant to Rule&#160;12a-8 thereunder.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjE4_74a8bb47-b090-46d8-a9ef-02d7d30eca7f">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1e2dc0430f3646028f457f8334a1c0cc_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, Verona Pharma plc announced its financial results for the quarter ended March 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-bottom:6pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01. Financial Statements and Exhibits.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.596%"><tr><td style="width:1.0%"></td><td style="width:7.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="vrnaq12023pressrelease.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="vrnaq12023pressrelease.htm">Press Release issued on May 9, 2023</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1e2dc0430f3646028f457f8334a1c0cc_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERONA PHARMA PLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May 9, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;/s/ David Zaccardelli, Pharm. D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name:&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;David Zaccardelli, Pharm. D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;President and Chief Executive Officer</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vrnaq12023pressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7358e6523b9640fb876ae00e6cdc5080_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:99px;margin-bottom:5pt;vertical-align:text-bottom;width:203px"></div><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">NDA submission on schedule for Q2 2023</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Strong balance sheet to support commercial launch preparations</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Conference call today at 9&#58;00 a.m. EDT &#47; 2&#58;00 p.m. BST</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LONDON and RALEIGH, N.C., May 9, 2023</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8211; Verona Pharma plc (Nasdaq&#58; VRNA) (&#8220;Verona Pharma&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2023, and provides a corporate update.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;We recently had a pre-New Drug Application (&#8220;NDA&#8221;) meeting with the US Food and Drug Administration (&#8220;FDA&#8221;) and are on schedule to submit the NDA in the second quarter of 2023,&#8221; said David Zaccardelli, Pharm. D., President and Chief Executive Officer. &#8220;We believe we are aligned on the content of the NDA for ensifentrine for the maintenance treatment of Chronic Obstructive Pulmonary Disease (&#34;COPD&#34;), which will comprise data from the successful Phase 3 ENHANCE studies and other completed ensifentrine clinical studies including data from approximately 3,000 subjects.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;As announced earlier this month, we are looking forward to presenting additional analyses from the ENHANCE studies at the American Thoracic Society International Conference (&#8220;ATS&#8221;) taking place May 19-24. We will present 12 abstracts and a clinical trials symposium on subgroup data and pooled analyses from ENHANCE-1 and ENHANCE-2 covering exacerbations, symptoms, quality of life, use of rescue medication, healthcare utilization and safety. An overview of the ENHANCE trial results will be presented as part of the clinical trials symposium reserved for highlighting new breakthroughs. The abstracts are published on the ATS website and in the publication, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">American Journal of Respiratory and Critical Care Medicine</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. We will be hosting a webcast and conference call on Tuesday, May 23, to discuss these data.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Alongside our progress, Nuance Pharma, our development partner in Greater China, enrolled the first subject in its Phase 3 trial evaluating ensifentrine for the maintenance treatment of COPD in China. This is a significant milestone and we are excited about the potential of ensifentrine to address the urgent global need for a novel therapy for COPD. We look forward to updating you on their progress.&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Program Updates and Key Milestones</font></div><div style="margin-bottom:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company&#8217;s near-term planned milestones include&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Presentation of 12 abstracts and one symposium demonstrating positive efficacy, symptom, quality of life and safety data from the ENHANCE Phase 3 clinical studies with nebulized ensifentrine in COPD at ATS in May 2023. The Company is holding an investment community webcast and conference call at 4&#58;00 p.m. EDT &#47; 9&#58;00 p.m. BST on Tuesday, May 23, 2023, to discuss these data. To participate, please dial one of the following numbers and ask to join the Verona Pharma call&#58;</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.4pt">+1-833-816-1396 for callers in the United States</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.4pt">+1-412-317-0489 fo</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">r international callers</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A live webcast will be available on the Events and Presentations link on the Investors page of the Company&#8217;s website, </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">www.veronapharma.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and the audio replay will be available for 90 days.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Submission of an NDA to the US FDA in the second quarter </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of 2023 for</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> inhaled ensifentrine for the maintenance treatment of patients with COPD.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="background-color:#ffffff;color:#232323;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Quarter and Recent Highlights </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Corporate</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">In April 2023, the Company held a pre-NDA meeting with the FDA. The submission, comprising data from the Phase 3 ENHANCE studies and other completed ensifentrine clinical studies including data from approximately 3,000 subjects, is on schedule for the second quarter of 2023.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Also in April 2023, the Company&#8217;s development partner in Greater China, Nuance Pharma, enrolled the first subject in its pivotal Phase 3 clinical trial evaluating ensifentrine for the maintenance treatment of COPD in China. In 2021, Verona Pharma entered into an agreement with Nuance Pharma for exclusive rights to develop and commercialize ensifentrine in Greater China, with future potential milestone payments up to $179 million plus royalties.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Quarter 2023 Financial Results</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.5pt">Cash position&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Cash and cash equivalents at March 31, 2023, were $291.4 million (December 31, 2022&#58; $227.8 million). The Company believes cash and cash equivalents at March 31, 2023, expected cash receipts from the UK tax credit program and funding expected to become available under the $150.0 million debt facility, will enable Verona Pharma to fund planned operating expenses and capital expenditure requirements through at least the end of 2025 including the commercial launch of ensifentrine in the US, if approved.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.5pt">R&#38;D Expenses&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Research and development (&#8220;R&#38;D&#8221;) expenses were $12.6 million for the first quarter ended March 31, 2023 (Q1 2022&#58; $17.6 million). This decrease was primarily due to a $5.1&#160;million decrease in clinical trial and other development costs as the Phase 3 ENHANCE program is in the final stages of completing data analysis whereas in the same period in the prior year significant costs were incurred associated with active enrollment.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.5pt">SG&#38;A Expenses&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Selling general and administrative expenses (&#8220;SG&#38;A&#8221;) were $9.6 million for the first quarter ended March 31, 2023 (Q1 2022&#58; $7.4 million). This increase was primarily due to a $2.7&#160;million increase in people related costs, inclusive of share-based compensation, as well as an increase of $0.8&#160;million for costs related to the build out of commercial infrastructure in preparation for a potential commercial launch. The increases were partially offset by a non-recurring $2.0 million charge related to the modification of the assignment and license agreement with Ligand UK Development Limited, which was incurred in the three months ended March 31, 2022.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.5pt">Net loss&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Net loss was $16.7 million for the first quarter ended March 31, 2023 (Q1 2022&#58; net loss $24.8 million).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Conference Call and Webcast Information</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Verona Pharma will host an investment community webcast and conference call at 9&#58;00 a.m. EDT &#47; 2&#58;00 p.m. BST on Tuesday, May 9, 2023, to discuss the first quarter 2023 financial results and the corporate update.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To participate, please dial one of the following numbers and ask to be placed into the Verona Pharma first quarter earnings call&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.5pt">+1-833-816-1396 for callers in the United States</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.5pt">+1-412-317-0489 for international callers</font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the audio replay will be available for 90 days. An electronic copy of the first quarter 2023 results press release will also be made available today on the Company&#8217;s website. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For further information please contact&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.681%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #cfcfcf;border-top:0.75pt solid #cfcfcf;padding:2px 1pt 2px 5.87pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Verona Pharma plc</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #cfcfcf;border-right:0.75pt solid #cfcfcf;border-top:0.75pt solid #cfcfcf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt;padding-right:4.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US Tel&#58; +1-833-417-0262</font></div><div style="padding-left:6pt;padding-right:4.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">UK Tel&#58; +44 (0)203 283 4200</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #cfcfcf;border-top:0.75pt solid #cfcfcf;padding:2px 1pt 2px 5.87pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Victoria Stewart, Senior Director of Investor Relations and Communications</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #cfcfcf;border-right:0.75pt solid #cfcfcf;border-top:0.75pt solid #cfcfcf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.85pt;padding-right:4.85pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IR&#64;veronapharma.com</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #cfcfcf;border-top:0.75pt solid #cfcfcf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.85pt;padding-right:4.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Argot Partners</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>(US Investor Enquiries)</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #cfcfcf;border-right:0.75pt solid #cfcfcf;border-top:0.75pt solid #cfcfcf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.85pt;padding-right:4.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tel&#58; +1-212-600-1902<br></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">verona&#64;argotpartners.com</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #cfcfcf;border-top:0.75pt solid #cfcfcf;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.85pt;padding-right:4.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Optimum Strategic Communications</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>(International Media and European Investor Enquiries)</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #cfcfcf;border-right:0.75pt solid #cfcfcf;border-top:0.75pt solid #cfcfcf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.85pt;padding-right:4.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tel&#58; +44 (0)203 882 9621<br></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">verona&#64;optimumcomms.com</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #cfcfcf;border-left:0.75pt solid #cfcfcf;border-top:0.75pt solid #cfcfcf;padding:2px 1pt 2px 5.87pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Mary Clark &#47; Richard Staines &#47; Zoe Bolt</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #cfcfcf;border-left:0.75pt solid #cfcfcf;border-right:0.75pt solid #cfcfcf;border-top:0.75pt solid #cfcfcf;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Verona Pharma</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma&#8217;s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company has evaluated nebulized ensifentrine in its Phase 3 clinical program ENHANCE (&#8220;Ensifentrine as a Novel inHAled Nebulized COPD thErapy&#8221;) for COPD maintenance treatment. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate and risk of COPD exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. Two additional formulations of ensifentrine have been evaluated in Phase 2 studies for the treatment of COPD&#58; dry powder inhaler (&#8220;DPI&#8221;) and pressurized metered-dose inhaler (&#8220;pMDI&#8221;). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">www.veronapharma.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Forward-Looking Statements</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our operational review, outlook and financial review, the development of ensifentrine and plans to release data from the ENHANCE trials at future scientific conferences, upcoming events and presentations, planned regulatory submissions and timing thereof, including the timing of submission of an NDA for ensifentrine</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and our expectations regarding the content of the submission, the planned US commercial launch of ensifentrine, the potential for ensifentrine to be the first therapy for the treatment of respiratory diseases to combine bronchodilator and non-steroidal anti-inflammatory benefits in one compound, the potential of ensifentrine to change the treatment paradigm for COPD patients, and the potential of ensifentrine in the treatment of cystic fibrosis, asthma and other respiratory diseases, as well as the potential of the DPI and pMDI formulations of ensifentrine, ensifentrine&#8217;s compelling benefit risk profile, the funding we expect to become available under the $150.0 million debt financing facility and from cash receipts from UK tax credits, and the sufficiency of cash and cash equivalents, and the cash runway period provided by the sources of financing through to at least the end of 2025 and expected to fully fund the planned commercial launch. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following&#58; our limited operating history&#59; our need for additional funding to complete development and commercialization of ensifentrine, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts&#59; the reliance of our business on the success of ensifentrine, our only product candidate under development&#59; economic, political, regulatory and other risks involved with international operations&#59; the lengthy and expensive process of clinical drug development, which has an uncertain outcome&#59; serious adverse, undesirable or unacceptable side effects associated with ensifentrine, which could adversely affect our ability to develop or commercialize ensifentrine&#59; we may not be successful in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">developing ensifentrine for multiple indications&#59; our ability to obtain approval for and commercialize ensifentrine in multiple major pharmaceutical markets&#59; misconduct or other improper activities by our employees, consultants, principal investigators, third-party service providers and licensees&#59; our inability to realize the anticipated benefits under licenses granted by us to third parties to develop and commercialize ensifentrine, our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel&#59; material differences between our &#8220;top-line&#8221; data and final data&#59; our reliance on third parties, including clinical research organizations, clinical investigators, manufacturers and suppliers, and the risks related to these parties&#8217; ability to successfully develop and commercialize ensifentrine&#59; lawsuits related to patents covering ensifentrine and the potential for our patents to be found invalid or unenforceable&#59; lawsuits related to our licensing of patents and know-how with third parties for the development and commercialization of ensifentrine&#59; changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments could affect our profitability, and audits by tax authorities could result in additional tax payments for prior periods&#59; and our vulnerability to natural disasters, global economic factors, geo-political actions and unexpected events, including health epidemics or pandemics like the COVID-19 pandemic, and conflicts such as the Russia-Ukraine conflict, which has and may continue to adversely impact our business. These and other important factors under the caption &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022, as updated in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#232323;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Verona Pharma plc</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#232323;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Consolidated Financial Summary</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#232323;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:139%">(unaudited)</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#232323;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.799%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.030%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Three months ended March 31,</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2022</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,610</font></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">17,625</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Selling, general and administrative</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,589&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,440</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">22,199&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">25,065</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Operating loss</font></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(22,199)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(25,065)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Other income&#47;(expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development tax credit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,313&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,302</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,677&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense</font></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(293)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(84)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Foreign exchange gain&#47;(loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">932&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(923)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total other income, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,629&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">310</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Loss before income taxes</font></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(16,570)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(24,755)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income tax expense</font></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(173)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(82)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net loss</font></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(16,743)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(24,837)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:2.5pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted-average shares outstanding &#8211; basic and diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">621,451</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">481,942</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss per ordinary share &#8211; basic and diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.03)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.05)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-31</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-31</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2022</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">291,415</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">132,764</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total assets</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">323,146</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">169,315</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Shareholders&#8217; equity</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">276,749</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="border-right:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">126,307</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 3.77pt 0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vrna-20230509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:02513115-553c-4185-be33-9e67d07cd5d7,g:7039ddd0-aa47-44f2-98f7-19a47995764e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrna="http://veronapharma.com/20230509" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://veronapharma.com/20230509">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20230509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20230509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://veronapharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>vrna-20230509_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:02513115-553c-4185-be33-9e67d07cd5d7,g:7039ddd0-aa47-44f2-98f7-19a47995764e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_7dd1c565-4e42-4688-9a87-871b5cb93c40_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_842c7956-b2f9-4830-9f75-6176d97cdec4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0b004ced-4219-4b2e-b9c8-7134176359b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bb3d04cb-dcd8-442a-8644-8287a35a32bb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b58ad360-bc6b-4dd1-b704-12c25442761f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_68ec2089-2560-4973-895e-64a65e8d52e1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_aa77af3e-cbcf-4b29-afa8-af05a587b65d_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_df0eb948-b308-481d-8569-8403d7f07c62_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_00aeeaf3-07dd-4564-b772-211e565f7257_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3a28601d-a6e2-47ae-9b0c-140c1eec6a90_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_42c324fb-01db-4078-ab8a-fab99c765c48_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5c2d4a85-fc0d-4032-b90d-bd77adbe79a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_251c695a-1415-49db-8758-3329d4b3aecf_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_14a28426-9c83-4bde-9549-4a792cc67df0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_128b5679-3de7-414b-9f1a-73066b6dda70_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a755922e-21d1-4be7-9219-58d1b5d28424_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d2efbab3-007d-4d2e-9b94-fefc59a059f5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_21c2715f-a59f-4ba5-9391-8bdb9a054a00_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_efd20b22-47e7-4091-ba4e-17131580f1ec_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_893492ba-3ad1-4f5b-82c5-ccd5ecdc4c45_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d6976dee-aa7f-4be0-8fba-1f2925fff3cb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_dbd560f5-866e-4d31-bcc6-3f7eda6e10e5_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_1282a1ca-c665-45a0-bfac-0a3ccea039b6_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>vrna-20230509_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:02513115-553c-4185-be33-9e67d07cd5d7,g:7039ddd0-aa47-44f2-98f7-19a47995764e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/Cover" xlink:type="simple" xlink:href="vrna-20230509.xsd#Cover"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_03dafb46-66c4-4e84-8fcf-16cba84512e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_DocumentType_03dafb46-66c4-4e84-8fcf-16cba84512e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b8265d87-6644-4630-adc2-7fa5d24cfcf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_DocumentPeriodEndDate_b8265d87-6644-4630-adc2-7fa5d24cfcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e94e720f-fbd2-46e0-9e16-10092e1ad3af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_EntityRegistrantName_e94e720f-fbd2-46e0-9e16-10092e1ad3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_99f9e2eb-7257-44f0-a1cb-a4c4cd5c14b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_99f9e2eb-7257-44f0-a1cb-a4c4cd5c14b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b8d0ced4-0949-4fe4-9d1d-7a4eafbf2482" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_EntityFileNumber_b8d0ced4-0949-4fe4-9d1d-7a4eafbf2482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_be40549d-1a1c-42d4-8bc2-f6e335d026f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_EntityTaxIdentificationNumber_be40549d-1a1c-42d4-8bc2-f6e335d026f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5b5d4577-7c0d-4e5f-8c8b-4fa55ae45b32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_EntityAddressAddressLine1_5b5d4577-7c0d-4e5f-8c8b-4fa55ae45b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9b1c1025-0c78-455d-a47d-507cab486f40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_EntityAddressCityOrTown_9b1c1025-0c78-455d-a47d-507cab486f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5c840bb9-a6a6-4b14-a4d2-b49c1d02a1dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_EntityAddressPostalZipCode_5c840bb9-a6a6-4b14-a4d2-b49c1d02a1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_c24c7da6-84f7-421b-9f3e-63b7ac9f6cc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_EntityAddressCountry_c24c7da6-84f7-421b-9f3e-63b7ac9f6cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_0b82b67d-9f4d-4e72-8501-667ef16d6e84" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_CountryRegion_0b82b67d-9f4d-4e72-8501-667ef16d6e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dcc5fc38-c0d6-40fd-bdf5-e018414584b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_CityAreaCode_dcc5fc38-c0d6-40fd-bdf5-e018414584b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_50a03685-27e1-4bee-9479-8f31798497f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_LocalPhoneNumber_50a03685-27e1-4bee-9479-8f31798497f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_1c91d6c1-2138-4e18-82a0-4a83a29ee92f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_WrittenCommunications_1c91d6c1-2138-4e18-82a0-4a83a29ee92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_9a0f02c1-b49a-4914-8a96-9b25e58c91ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_SolicitingMaterial_9a0f02c1-b49a-4914-8a96-9b25e58c91ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_8419b1de-ad71-4a22-ab00-67f19a87dd74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_PreCommencementTenderOffer_8419b1de-ad71-4a22-ab00-67f19a87dd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_322ef80f-78fa-4ec7-b4df-1303bbf43911" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_322ef80f-78fa-4ec7-b4df-1303bbf43911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_56c97849-3923-4589-ae4b-9877568ce0ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_Security12bTitle_56c97849-3923-4589-ae4b-9877568ce0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_76890f1b-d257-40b8-a367-1ee8758be9ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_TradingSymbol_76890f1b-d257-40b8-a367-1ee8758be9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_51273976-b650-446d-ac45-107510e0fd26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_SecurityExchangeName_51273976-b650-446d-ac45-107510e0fd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a4dafd46-d147-4906-b92d-f52f70a902ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_EntityEmergingGrowthCompany_a4dafd46-d147-4906-b92d-f52f70a902ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_808b147c-8ba1-4392-bb24-155b622ebd02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_EntityCentralIndexKey_808b147c-8ba1-4392-bb24-155b622ebd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cf2f0525-a0d2-4b75-95e9-97555bba424c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_12932db6-1458-4085-9693-b51c484ac90d" xlink:to="loc_dei_AmendmentFlag_cf2f0525-a0d2-4b75-95e9-97555bba424c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  !E(   ,5" (   "#3O[&  "  $E$051X7NS=
M>7Q,U_L'\,D>LHB$2(@E8BF"H%HBQ*[47GL22Q51T2JEEBAM*;4T;76QQ)*J
M/?JUBWVI$!%56T010H(0$DEDS^1WY?QR>O)D9C)99X;/^Z^XSW/.?>Z=\<<\
MKW//E>4          "@2&1F9EI9&CP+H"!D]          !OO+2TM(X=.\ID
M,AL;F[-GS](P@"Y VPL         J("  %F>;MVZT3" +D#;"P        "H
M<>/&H>T%N@YM+P        "@6K9LR=M><^;,H6$ 78"V%P        #DDYF9
M:6IJRMM>NW?OIAF@L]+3TU-24NC1UQ3:7@        "03UA8&.]Y21X^?$@S
M0#?-F#'#R,C(P,"@9\^>L;&Q-/S:0=L+         /)9O7HU[WDY.#C0,.BF
M)4N6",U,6>_>O6G&:P=M+P        #-2$A(.'GRY//GSVE T\:/'\^;(P,'
M#J1AT$'2E\W2TE+H>LD,# S2TM)HWNL%;2\         #;ASYXZMK:U,)JM4
MJ=*E2Y=H6*-:M6K%FR.+%R^F8=!!BQ8M^J_CE<O,S"PK*XOFZ;[P\/"0D!!V
M:6A[ 0       &C O'GS> -BW+AQ-*PYF9F9)B8FO+;CQX_3#- U:6EI=G9V
M_#-E)DR80/-T679V]A]__%&O7CUV=8T:-8J*BD+;"P       $ #Q+97OW[]
M:%AS_O[[;UZ8GIY>?'P\S0!=LVK5*OZ9,E965D^>/*%YNDDNEP<&!C9NW)A<
M8Z]>O=#V @       -" 'W_\D?\^=W=WIV'-6;-F#2^L4:-&- RZ)CL[NT&#
M!OPS9?S\_&B>;MJW;Y^+BPNY.L;<W!QM+P         -V+AQ(_]]+OUNIV'-
M\?;VYH6-&C6*AD'7[-BQ@W^@S%MOO969F4GS=,V1(T?>??==<FDBZ3+1]@(
M      #0@/W[]_/?YXZ.CC2L.:U;M^:%_?+++S0,ND;\0)F@H"":I%-.GS[M
M[NY.+HK0U]</# Q$VPL       !  \Z=.\=_HEM;6].PAF1E99F:FO+"0D-#
M:0;HE&/'CO%/D^G=NS=-TAW2%[)'CQ[DB@A]??U>O7J=.7,F!V]R!
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M1].P=O#S\^-%2A8L6$ SM$!J:JI4IZVMK5@J8VEIZ>/C$Q$10<<4'=I>
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M?KQP':]HPPL<&3<W-U[5HT>/:%BC%BY<R JSM[=/2DJBX3<;VEX
M&C-V[%C>3PD*"J)A-5A86/ 9F**^Q>^33S[A8]>O7T_#Y2(Z.MK8V%BX""U:
MZI66EF9B8L*J:M:L&0UK5&IJJJVM+:LM("" AM]X:'L!      ! F8N(B!@Z
M=*B'A\?-FS=I[,TV??ITWNC9MFT;#1<F,S.3#V<L+2UI4F':M6O'AU^[=HV&
MR\64*5.$BWCEU*E3-$E#SIPYPZN:-FT:#6O4;[_]Q@I[]]UWM6<C>>V!MA<
M      "4N?KUZ[,?Y_;V]D^?/J7A-]BB18MX2V7UZM4T7)BXN#@^G*E7KQY-
M4DDNE_.=H:0_LK.S:4;9D[X2?$]]IG/GSC1)<Q8O7LP+.W3H$ UK3E96EI.3
MDU25GIZ>!M^_J<W0]@(      ("RE9Z>+CZ_-GSX<)KQ!ENU:A6_,TN7+J7A
MPMR^?9L/9]JU:T>35 H/#^=C.W;L2,/E8LZ<.<(5O*(E+W!D>O?NS:HR,3%)
M24FA8<W9MFT;*VSDR)$T!KG0]@(      ( RU[]___]:&C+9WKU[:<:;:L>.
M'?RV^/KZTG!APL+"A/OZRH ! VB22ALW;N1C9\R80<-E+R$AP<K*2K@"[5KJ
M)9?+*U>NS KKVK4K#6M4RY8M9;EK]!X^?$ACD MM+P       "ASD9&1_$DZ
M28T:-5Z\>$&3WDC'CAWCM\7'QX>&"W/TZ%$^G)DP80)-4DG<5&O'CATT7/;X
MBP@YK5KJ=>W:-5[8=]]]1\.:<^3($5;5HD6+: SRH.T%        Y6'ERI6\
M?2#Y\,,/:<8;Z=*E2_R>>'EYT7!A @,#A9OZRMRY<VF22NW;M^=CHZ*B:+B,
MI:2D5*U:52A?UJ5+%YJD47S/>(GT8=&PY@P;-DPJR<G)*2TMC<8@#]I>
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MC/7''W_P@5]__34-ES'R99"</GV:)FG4@P</>&T;-FR@8=!Z:'L!      !
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MW[^?)BGQ^>>?\U%7KERAX;(Q:- @H5CM7>HEZ=NW+RMR[=JU- :Z VTO
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MXR->FJNK*\U0HG/GSFR(C8T-C96!:=.FB75J^5*OF)@85F>'#AUH#'0-VEX
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M9\_F\\OE<AHNL:%#AXKU_/WWWS1#BYT\>=+0T/"KK[ZB =!Q:'L!      "
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M%Z^=IU!R<K*-C0VO8># @30#<DG_*9R<G/B-XIHT:5+4!W*AJ-#V @
M@.*X??MVP1_S]>K5NWOW+DTM+Q]^^"&O9,B0(32L4F)BHI65%1_NX.!0O W+
MO+V]^21>7EXTK%*'#AW8P#ESYM!8?O[^_OPLDI,G3](,P=RY<UE:DR9-:*P$
MEBU;Q@O0T]/[YY]_: ;DY"0D)+BXN/ ;Q;5NW3HN+HYF0VE#VPL       "*
M*38VME6K5N3W?/7JU:]?OTY3RT5"0H*#@P.O9->N731#I?GSY_]W&3+9NG7K
M:(8:MF_?SF>H4Z<.#:O4OW]_-M#'QX?&\A-;3I+P\'":(>C5JQ=+&S-F#(T5
M5UI:FKV]/2_@@P\^H!F0DY.:FNKN[L[O$M>Q8\?$Q$2:#64 ;2\        H
MOJ2DI.[=NY-?]=;6UN?/GZ>IY>+@P8.\#'M[^R)M-Q87%V=F9L:'-VO6C&:H
MX<F3)^+++J.CHVF&<GRU6J'+Q'Q]??DI)*K7#?'^U*^__DICQ25-Q<^.I5X*
M965E]>O7C]\EKG?OWJFIJ30;R@;:7@       % B&1D97EY>Y+>]N;GYT:-'
M:6JY^.BCCW@9HT>/IF&59LR8(5R$[,"! S1##<V:->,S;-Z\F8:5^_SSS]FH
M0E]&Z>/CPT]A8&"0G9U-,_*(N^R'A871<+%D9F8Z.CKR:8NWU"LK*RLY.9D>
M?8V(C]QR(T:,D.X>384R@[87        E(*9,V>27_C&QL8[=NR@>67OQ8L7
M-6O6Y&4$!071#.4>/7ID:FK*QW;JU(EFJ&'*E"E\AHD3)]*P<M]^^RT;Y>[N
M3F/Y>7IZ\E/8V]O3L&#W[MTLS<3$I'B[E16T8<,&?G8]/;TK5Z[0C,*</7N6
M-<Y&C!B1E95%P[J/]$\9Z<N@HD$)90%M+P       "@=?GY^^OKZXN]\ P.#
MM6O7TKRR=^C0(5Y#[=JUDY*2:(9RDR9-$JY =NG2)9I1F#U[]O#A39LVI6'E
M5JY<R4:YN+C06'Z]>_?FIVC>O#D-"[[\\DN6UJ9-&QHKENSL[$:-&O&S#QHT
MB&84)B$AH5:M6GR&X\>/TPP=1W9>8V;.G$GSH.RA[04       "E9LN6+<;&
MQN*O?3T]O>7+E].\LC=^_'A>0Y&67-V]>]?0T)"/'39L&,TH3$)"@H&! 1LN
M7?[SY\]IAA)\.WQ'1T<:R\_-S8U7V*U;-QH6O/_^^RQM\N3)-%8L.W;LX*>6
MKN[RY<LTHS#B4C7)B1,G:(8N"P@($#=W8Q8O7DSSH%R@[04       "EZ=BQ
M8Q86%N1G_^S9LVE>&4M,3.1+BO3T]$Z?/DTSE!LS9@ROW-#0\/[]^S2C,.^\
M\PZ?8>_>O32LQ)$C1]@0:VMK&LO/V=F9S^_AX4'#@NK5J[.TC1LWTEBQM&S9
MDI]Z\.#!-%P8L6LF<7-S>YT><I0^:[%G*M'7UU^Y<B7-@_*"MA<       "4
MLDN7+MG9V8D__B7>WM[EO+$1[R))ZM>OGY*20C.4N''CAOBTYJ>??DHS"B/N
M=#9CQ@P:5N+BQ8MLB*&A(8WEY^#@P.>?.G4J#>>)B8GA:3=OWJ3AHCMPX "?
ML!B[>CU\^-#&QH;/8&5E%14519-TUIDS9RI4J,"O3I;[.1;IG090ZM#V @
M    @-(7&1E9OWY]L04@RWU@L+1V55>3M[<W/_NT:=-H6+DA0X;P@186%@D)
M"31#I<.'#_/A;=NVI6$E[MZ]RT>I?LNAN;DYSU3Q -W>O7M93J5*E>1R.0T7
MG?AP93&6>KWWWGM\N&3[]NTT0V==N7+%RLI*O#I34U/U%_I!&4';"P
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MRKU\^;)!@P9\K*VM[:-'CVB2;I+^4_#KDKSSSCO/GCVC2:!I:'L!      !
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MR]8&#1I$PP7,G3N7%Z9BUWF"[PS5K%DS&BN -_X4KD[*S,SD!1@8&"C<TVW
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M5^7EY44SRE)Z>GK?OGWYV3GI:[]Y\V::K1Y?7U\VB70K[MZ]2\.@.]#V @
M    >!W$Q<6I;GY5J%!AQHP9)=EXJU ;-FP@SUU*)_WUUU]IGGI24E)(*\W"
MPN+HT:,TKS2<.W>.+U8:.7(D#><7$Q-C;&S,D@T-#=5IB]R[=X]?A?0QT7!^
MW;MW9YE25326DQ,6%L:GZM:M&PWGY 0%!;%HY\Z=:4P-?_SQ!Y]?S:5>TAWC
M0YR<G!(3$VE&F4E-3>W1HP<_.R?]1RCV5V7]^O5LDJ9-FSYZ](B&0:>@[04
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M'C4U->30)'JW?ZFE4L^>/;.SL^MNZ24# X.RLO+9LV=K:VNI+<'O#,)>
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MLK:V-@L+"S$2,GEY>7]__\K*2FK+O\F'#Q\2$A+0_S'0"]GE>L8_&(2]
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MB:;:W=W=R,A(1D8&;^3\3GQ\?'/GSK6PL/#U];U^_?K[]^^I5P7_'0A[ 0
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M%RXT-S>3:]ZY<\?'QP>-7$Y.CK(<K$O\_/QSY\ZUM+3T\_.[<>-&>7DYZ<H
M_(H@[ 4         X+_7U-2$,Y'=N7,G+BXN,##PR)$C#@X.9F9F>GIZ"Q<N
MG#9MFHB(R-"A0QD9&:GQF.\S8,  /CX^24G)N7/GHFM96EKNV;/GV+%CT='1
MMV[=0D/Z\.%#+[]L^.G3I\3$1"<GIWGSYO6\D[%+=G9VU!Y[!PTO*2EIY<J5
MY  B/3W]G#ES @("T*C:V]N+BHIB8V-W[=JU9,F2T:-'_^^J76%@8! 6%E93
M4]NV;=OITZ?3T]._/SX(P,\'82\          +^3]O;VZNKJHJ*B[.SLI*0D
MO(AL[]Z]6[9L,30TU-34G#-GCH2$!#\_?S\N(F-@8.#AX9DX<>+LV;.7+5MF
M8F+BZ.CHY>45'AZ>DI+RZ-&CTM)2\EJJ#EHHZN'#AWY^?@8&!L+"PM0>.^'F
MYOZ&79F%A84[=NP8.7(DN2MQ<7%[>_O(R$A_?W]34U-Y>?F>8W #!@R8,&'"
MTJ5+'1P<0D-#'SQXT*=/.@+PRX*P%P        " /U9C8^.[=^_R\O+NW+ES
MX<*%P,! =W=W>WM[4U-375W=!0L63)TZ%2\BZWG[82\-&3)DW+AQ\O+RFIJ:
MZ]>OM[.S0Y<[>_9L0D+"Y<N7CQX]:FYNCLYVF1[>PL*".OJO:6EI86=G)W="
M3T^/;@>-H8?;86-CFSQY\LJ5*UU<7&)B8IX\>4()V 'PQX"P%P
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MSIPY=>K429,FB8J*"@D)\?+RHHD:.'!@YQS_H+_,G3NWMK:6^FC_#A#V @
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M'P&@HVVNU-34O'/G#K7!-\%?,T!/I//J/ IT75E967M[>S3SY(<"_EH0]@(
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M/7?N7+\LT\-*2DK\_/S4U=79V=FI%_LW]'06+5KDX>'Q^/%C:B_@KP%A+P
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M,=[>WN0-I-\/O5>)B8E65E8X]W_/1HP8L7KUZN#@X'?OWE$[ G\T"'L!
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MEY654=M\MQ<O7GAX>,R?/[^[581DDR9-VK)E2T)"0O^&X<"O"<)>
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MGA['CV)C8W%EO)8J.3D9'UZZ=(G<:NS8L72T!67XD!S.(Q*0G3MW#I<L6+
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M9PL7+DQ.3J8V^Y'0D (" M!CPL^K-Z2DI+9MVY:4E%175T?M#OP"(.P%
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M&S;H;JR6H,3ECA\_/GSX</E*35/8VMK6J5-GQHP95Z]>C8R,Y"-"$D';"P
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M'#G$WXX]H)<XGCU[MG3ITD:-&JF/MAF7+EVZ-FW:K%RY4N\&<Y"8T/8"
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M9<J??OK)?-Z?*/ZY7;Y\^9=??C&^T%B7^ .)?QJS9LVZ?OVZ6?V;_>*@[04
M     /"%>?SX\<*%"QLT:&!\.VU1%9DE2Y;H;0,EK?W[][-7**K*ER]_X, !
M?L[G7KUZU:Y=._6L'#ERJ+M6J>[<N>/DY*2&<^;,>?'B19Y3W+]_GSHLQ8L7
M?_OVK5I]^?(E]8E2IDS)=F@2-UP^?28^HWJ<F3)EBARA5Z]>='#DR)'R(-V!
M:]>NR2/3IDVC&!DU:I2LTE+*B(B(;-FRR8/"Y,F3U?R$"1/D\29-FJC'CQX]
M2GV99<N6J27AT:-'-&:,.E\A(2&#!P]6'^5KW;HUNYDQ$AP<O&#!@NS9L].
MNJRLK-JT::-WB6L2\O+RVK!A0]NV;8UO6*8K8\:,+BXNJU>O-L-_R.8/;2\
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M0I8L61+M+O+B#N_;M\_<GI827V#QQ1@[=FRI4J7XC*,COHT#!PX4?W3=%S6
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M86%A8C[JDTK9LV?7^RP>F$A\M<Z<.3-V[-AFS9J)?R;L&<.O&]I>
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M;&QLU-%BM'5]O @-#75V=J8)B,]BZ.DM8?#@P92TM+34N_N5M'/G3ADK4*!
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M4R/]1&',F#$4+E6JE*$W8\:(M[=WBQ8M:%B-MI&W8\<.GH-O&]I>
MWXI#APY5KUY=[13HLK2T;-^^/7O@R$1/GCQIW+@Q&[!BQ8JQV[H^+L+"PIHU
M:T9S:-FRI=X-VB575U=U(_^:-6L:"<^;-T_&*E6JQ&M&K5V[EBYQ[]X]5KUP
MX8(LI4Z=FI6"@X-E*5>N7*RD:_'BQ3+LZ.C(:\K:3*ELV;(\\4FC1HUDIDR9
M,H;:A3U[]J2AIDR9PLN?&SY\.(7CJ_,EK%Z].E6J5#2RT+%CQW?OWO$<?*O0
M]@(      /CZN;N[JQM7Z65A8=&F31M75U=^L@E"0T.G39M&R_2DU*E3+UFR
MQ%#3).&$AX>W;-F2IM&X<>.PL# >^N3]^_>%"Q>F<,:,&8UL/>;CXY,N73J9
M/'/F#"\;U:%#!WEBYLR9>>W#ARU;MLAJT:)%64G<6UG*EBT;*^FZ?OVZ# NZ
M>[VKK3?)T,-<#QX\H#6JXH_(RUK!P<$E2Y:4&2LKJ[___ILG/D=;FVGBM?/U
MWW__5:Y<F486<N3(<?3H49Z#;Q+:7@       %^_>O7JJ7T!QL+"HD6+%K=O
MW^:GF>;HT:.T[H^T:M7JU:M7/)KP(B(BVK1I0],0'SPD)(2'%&*>%!;WX="A
M0SRA^.FGGV3RAQ]^X+7H9,V:59[;NG5K7OOP8>;,F;):OWY]5@H/#Y>E3)DR
ML9(N\?'IZ2?=-8SOW[^G/;FD=NW:L0P9,6*$S*1+E\[+RXN7M1X^?$B7RY@Q
MHYN;&T]\KF_?OG3ITJ5+QU?G2WSJ7W[Y17TS@_A3#APX,"@HB$?A&X.V%P
M    P%<N-#34R-;U39LVO7[].C_'-*]>O7)Q<6$#YLZ=^^#!@SR:*"(C(]NU
M:T<SJ5&CAO$-Q>;,F:-,7#-JU"B>4#Q^_-C6UE:C?;(IIL_$W;Y]FZZB]^&I
M?OWZR6JW;MU827PH64J;-BTKZ45OKM2[(7VG3IUD51*?R-!.\'Y^?IDS9Y:Q
M[MV[\_(GZK9H%2M6%%\VGE!$146)H2A?IDP9'Q\?'HJMBQ<OTMLPI4*%"HF#
M/ ??$K2]        OG(1$1%ITZ95VP&2L[/SY<N7>=HT8LSY\^<[.#BH UI;
M6X\<.=)XIRGA1$9&=NS8D293J5(E?W]_'E*</GU:?3ZH2I4JQE_+2)N%]>[=
MF]>B,W?N7+K0W;MW>5G92VO"A FL%!45)4NI4J5B);TF3YXL\WKW CMV[)BL
MDNG3I_/0)VO6K)$92TM+(_VC 0,&T&A]^O3AY<^)/Y/:>BM=NG0\=KX" @+4
M'<<TVN^DN*5&5KG"UPUM+P      @*_?TJ5+U5Y _?KU+URXP$,F.W?N7*E2
MI=0!A<J5*]^Z=8M'$TM45%27+EUH,F7*E#&^K_GKUZ]IU:%&NX[O^?/G/*0X
M>?*D3*9(D4*<R\O1<79VEJ=GS)A1[TL/BQ4K)@.Z+WD4Y,-ZR9,GYP5]U,;6
MLV?/6#4R,I*]9[-9LV8L0\14RY<O+V/B/_3._(/V<<)RY<K1@.O6K>.)SXDY
MJ \)1OO'BJD]>_:(^TSCRTOH[3;"5P]M+P      @&_"QHT;FS5KUJ=/G[-G
MS_*:R;R]O7OTZ,&63*9)D^;WWW\WU!-)!&SI7+%BQ<0\>4@1'A[.WFBY9\\>
M'E*(\<N6+2N3/__\,R]')S0TE';4:MFR)2]KT0Y9^_?OY[4/'ZRLK#3:Q96\
MH$] 0  ]Q;9V[5I>_O!AXL2)LBH-'SZ<)Q3GSY^G/_>R9<MX^9,G3YZ(KX&,
MV=G9W;QYDR<^%Q$1\>.//](<XG>UH_#FS9N&#1O2^!IMTW#NW+E)^"V%)(&V
M%P       $0O*BIJY<J5Z=.G5UL)0ILV;6+Q]%/\ZMV[-\VG4*%"AC:K(D.'
M#E4^@6;PX,$\\;EUZ];)9*9,F8POG-3KU*E3=*U%BQ;Q\H</;]^^I8#>?=:H
MC<4+!M"S5UVZ=.$U;1ONN^^^DX%BQ8H9VJZ>T)I$\=<WTIS:O7NWC GY\^?W
M]?7EB<^%A871NE&A;-FR\?O,E[!X\6([.SNZA%"K5BW=)^#@*V;JOQD
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M0F[9LH4G#'-U=:4W8PK5JU>/MM$6=^(2/7KTH(M*N7/GCOLW!!('VEX
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MS!/1.73HD+I"MG;MVD%!03R4D#9MVI0F31J:@"2^!J:OM(6$@[87      #
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MWKU[>5E1L6)%&3.^:M*(L6/'TK6V;MW*R_$G*"B(-GI/GCSYDR=/>$*?P,#
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M[MRY/&&"-6O6J%W1>O7JF;C%6/PZ=.A0EBQ9E$_S4?'BQ6_<N,&CD)#0]@(
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M/5+?>%"S9LV8_I6EN7/GTB#"]]]_GU2=+_&)Z*4$Q-[>WOCK.R%>H.T%
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M[=NW\X1IIDR9HH[S_???F[[16+P[?_Y\OGSYU/D(KUZ]XCF(/VA[ 0
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MRY<OYPD3O'OWKF'#ABE2I&C:M&E<MIQCGC]_GCMW;IJ;1MOYBL<_ 20TM+T
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MIDSW[MWC.?,P=>I4FF>Y<N5,;"3%Q?OW[]5=L9R<G'C"L&/'CM&)CHZ.O&R
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M6=Q,/S\_GDA<PX</I_EDRI0I";<;,^3:M6MITJ2A20KMV[='Y\MLH>T%
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M.7/FT'7_^NLO7HX/Q8H5HTM4K%B1EY..JZLK+1X41HX<R1, AJ'M!0
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M;!E=?<&"!;P<3]0=Q(0C1X[P1%)S<7&AZ25+ENS1HT<\ ? YM+T       #
M3/W]]]]*'T:S:=,FGD@4:K=%Z-"A T\DL!4K5M#5Y\R9P\OQY,J5*\JGU(P9
M,X8GDIJ;FUN*%"EHAL[.SCP!\#FTO0       , <149&EBA1@GH<9<N6C8J*
MXJ&$)RZ:*5,FFH8F(7?7,F3ERI5T]1DS9O!R/ D/#[>WMZ<+5:E2A2?,P)0I
M4VB&PIX]>W@"0(&V%P       )@C]1$GX=BQ8SR1*&[<N*%.0WCX\"$/);#5
MJU?3U:=,F<++\:=.G3IT(1L;&S/<-CXX.#AW[MPTR3QY\H@C/ 3P"=I>
M    8';>OW^?)4L6ZFXT;-B0)Q++[-FS:1I"UJQ9>2+AK5V[EB8P<>)$7HX_
M8O#_?52-YN^__^8),_#77W^IDYPT:1)/ 'R"MA<       "8G7'CQE%?P]+2
M\M:M6SR16+[__GNEQZ)Q<7'AB82W?OUZFL#8L6-Y.?ZPS=02]%IQ\=UWW]$D
MDR=/_N3)$YX T$+;"P       ,S+BQ<O[.SLJ*_1I4L7GD@L(2$AZA[JPA]_
M_,%#"6_CQHTT@9$C1_)R_/'W][>RLJ)K5:U:E2?,P^W;M]5Y-FW:E"< M-#V
M @       //2H4,'ZF@D3Y[<S<V-)Q++\>/':2;2O7OW>"CA;=JTB28P9,@0
M7HY7I4N7IFN9Y_9>TH ! VB>PH$#!W@" &TO        ,"N7+U^VL+"@=L:H
M4:-X(A&-&3-&::UH,F?.S!.)8LN6+32' 0,&\'*\&CAPH/*)-4>/'N4)\_#V
M[=OTZ=/3///GSQ\2$L)#\,U#VPL       #,2/7JU:F7D3Y]>E]?7YY(1.7+
MEZ?)"*U;M^:)1+%MVS::0Y\^?7@Y7JDM-F'\^/$\83:6+EVJ3G7JU*D\ =\\
MM+T       # 7+"7],V=.Y<G$I&/CX^EI:4ZGR5+EO!0HMB^?3O-H7OW[KP<
MK]S<W)1/K*E6K1I/F(V(B(@2)4K05+-ER\83\,U#VPL       #,0FAH:+Y\
M^:B+D2=/'G&$AQ+1CAT[:#+2W;MW>2A1J-W 3ITZ\7)\RY4K%UW.UM8V*"B(
M)\S&B1,G:*KBR\/+\,U#VPL       #,PJ)%BZB%(?SYYY\\D;AZ]^ZMSB=C
MQHP\D5AV[=I%TVC7KATOQS=Q">5S:XX=.\83YD1\;5*G3ITS9\Y#AP[Q&GSS
MT/8"        L^#BXD*MEC)ERD1%1?%$XE(?/1-:MFS)$XEESYX]-(U6K5KQ
M<GQC>V9-F#"!)P"^$&A[ 0      @%G8N'&C[+-865F=/GV:EQ/7DR=/U-:/
ML&C1(AY*+/OV[:-I-&_>G)?CVZU;MY3/K:E>O3I/ 'PAT/8"        <[%O
MW[[QX\=?O'B1%Q+=LF7+U-:/<.O6+1Y*+ <.'*!I-&[<F)?C6V3D_[%W)U!2
M5(?ZP$G.R4M>!E<4C<;ER'-)8HS&Y>\6)6YH])CHDPD2Q)&#!)$H;R0XAQ!
M''"<$/9=9!,1644$1&%Z>O:>?=_W?=_WZ>[YWV',V-P[]%;WWJJN^G[G.^^\
M]VC[5M=T=]WZNA;;)9=<,C+BCW_\XYZ>'OI! +X M1<         ;?+DR2.]
M#S%NW#@53[H\=>K4R)),FC2)_F<!GGGF&8=7/R8L+(Q^!( O0.T%
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M0EK#_OWO?],/DBLB(F)D86Z__7;ZG\4X<N2(PSH8,W'B1/H1 )J'V@L
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M#3?<X%CT7'311:I?V(M(2DH:6:1++[V4_F>1QHT;Y[ ^QD1$1-"/ - PU%X
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MP8[E#K%\^7+Z02K)S<UU7+#.SD[Z$2(%!04YCO[$$T_0CP#0*M1>
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M : ]J+T         P#6+Q7+++;>,&3/F]MMO3TE)H?\90'M0>P$       "
MN[JZNNC_%X!6H?8"           =0NT%           ZA-H+          !T
M"+47          #H$&HO          #0(=1>          "@0ZB]
M  ! AU![ 0        " #J'V @          '4+M!0          .H3:"P
M        = BU%P          Z!!J+P          T"'47@          H$.H
MO0          0(=0>P$         @ ZA]@(          !U"[04
M #J$V@L          '0(M1<          .@0:B\          - AU%X
M     *!#J+T          $"'4'L!         ( .H?8"           =0NT%
M           ZA-H+          !T"+47          #H$&HO          #0
M(=1>          "@0ZB]          ! AU![ 0        " #J'V @
M    '4+M!0          .H3:"P          = BU%P          Z!!J+P
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M"E@;==-,=H.N;DQC_:-NG)GT^X79KZTK?O_SFD],;0D%]KX!^C5H$FHO
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M/M_$W6F((Y6*W]O'OG9>Z2ZLH<<#    Z81N[GTZ,;?.[LPJI]>7 *B]
MP+GO:R\B[:40=JO//7*F0>HB4R7VA7-)TJ,+Z<$   ! NOHCL>QF&AE)Q%73
MF\^DT6N--]1>    X-QYM5?=@2AVJ\\])<$ZOY]C1THQ^ZIYI6+C"7H\
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M"ZKI@7V4S19UPTSV!7))SIM;Z.$   ! HC9+'KN!1KQ.\J2E]"KV"FHO
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MA%\ZI:^VA5Y$3Z#V @   .=<U%Z5VTZS\P#N\>G[.=K[!\3]=EH2O)\>#P
M .3J*:YEM]%\T_"EA1Y5BM[*QKK/(]-?"C%=)/P _U&C<*J#V@L   "<<U%[
M]3>TF2Z>PDX%^*;T0Q\^S['AJP3V%?%*5UX5/1X   #(U9%6PFZC><;/?Z"E
MDQY5KKZ:YJ(E^\Q73*.737"B;IQI'[#22^,VU%X   #@G(O:BTC]4S [%>";
M^/M]^#S'K("U["OBDO@'%]"# 0  @'1M<7GL9IICM-.P]-4T9\U8SRZAT+2$
M9]#+X3;47@   ."<Z]JK]E,S.Q7@GI[B6GI@7V#KZ3./%_6[:/GJ8_1X
M(%UK;"Z[F>:8Q(D+Z2%55;L_TCQ>U 4<V!0&[:&7P&VHO0   , YU[67M;T[
M_'+A=R\J#3U"#^P+ZH_&LJ^%3_S\>\L;Z/$   ! .M&U5\JSR^@AU=:>7!3Q
MLP!V444D[LYY]/!N0^T%    SKFNO8B,OZQD9P-\$_^ 3Y[G*&[-)#^YF!X,
M    U""Z]DK_WQ7TD!K0GEPD[I!V*CVE=?3P[D'M!0   ,ZY57LU'+.PLP'N
MZ2GQ<L:C%EM7K[@KOU9]=)H>#P   -1@S-J+J-TGXTH7))5;OZ;'=@]J+P
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M%X]+6F/X[/3JOO8J#-K%+AO?:&>35KST,W;Q^$;A'1(-57O5?A;!+B2O:.$
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M(JY^E5TJ7O'Z<"=IQ)6M)-DSU]'CN0>U%Z^H6WN1"7K5]F^$WBE5LY$S!9<
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M&TM![ 4          %X(L1<          '@AQ%X          ."%$'L!
M     ( 70NP%          !>"+$7          !X(<1>          #@A1![
M 0        " %T+L!0          7@BQ%P          >"'$7@
MX(40>P$         @!="[ 4          %X(L1<          '@AQ%X
M     ."%$'L!         ( 70NP%          !>"+$7          !X(<1>
M          #@A1![ 0        " %T+L!0          7@BQ%P
M>"'$7@          X(40>P$         @!="[ 4          %X(L1<
M     '@AQ%X          ."%$'L!         ( 70NP%          !>"+$7
M          !X(<1>          #@A1![ 0        " %T+L!0
M7@BQ%P          >"'$7@          X(40>P$         @!="[ 4
M     %X(L1<          '@AQ%X          ."%$'L!         ( 70NP%
M          !>"+$7          !X(<1>          #@A1![ 0        "
M%T+L!0          7@BQ%P          >"'$7@          X(40>P$
M    @!="[ 4          %X(L1<          '@AQ%X          ."%$'L!
M         ( 70NP%          !>"+$7          !X(<1>          #@
MA1![ 0        " %T+L!0          7@BQ%P          >"'$7@
M    X(40>P$         @!="[ 4          %X(L1<          '@AQ%X
M         ."%$'L!         ( 70NP%          !>"+$7          !X
M(<1>          #@A1![ 0        " %T+L!0          7@BQ%P
M    >"'$7@          X(40>P$         @!="[ 4          %X(L1<
M         '@AQ%X          ."%$'L!         ( 70NP%          !>
M"+$7          !X(<1>          #@A1![ 0        " %T+L!0
M    7@BQ%P          >"'$7@          X(40>P$         @!="[ 4
M /^R8\>.KQ7[ZZ^_^/( BJ6FID9&1IX]>S8@(&#KUJVK5Z_>MFW;_OW[3Y\^
M?>?.'?YJ      /<NG7KPH4+-!L)"@J*B(BX=^\>?P5X,L1>  #P+\\__WPA
MQ7[[[3>^/("LR,C(=>O6??KIIT\\\01?G_ZM6K5JK5JU^OSSSP\<.)"6EL8+
M 0   *AU\N3)"1,F-&C0H%BQ8GP*4JB0GY_?>^^]]^VWW\;'Q_,EP=,@]@(
M@']![ 5&R,[.WK9M6\.&#?DZI$S1HD6;-&DR;MPX6N6RLK)X=0     %[MZ]
M.W/FS,J5*_.IAH3[[KNO18L61XX<X87 <R#V @" ?T'L!?K*SL[^[KOOZM6K
MQ]<>M7!I+0   (BRV6RK5JU2'G@Q[=NW#PT-Y47!$R#V C>[>_=N<'#PSS__
MO&+%BEFS9LU49L:,&?/FS5NY<N7FS9M__?77HT>/GC]_/C$QD5<' '&(O4!'
M:6EI7;ITX>N--M:/O0X<.,#W6[+P&S( 0+YHFL&WF-)V[=K%EP?X1U14U$LO
MO<2G%((*%RX\=^Y<7AHL#[$7N,>=.W>^^>:;]NW;%R]>G&].-/#S\VO2I,G0
MH4-_^.$'I&  ZB#V KW<O'GSY9=?YBN-9M:/O?[SG__P0<OZO__[/UX"  !R
M<OKUZ\>WF-(^^>03OCQ KI,G3S[ZZ*-\C?E'U:I5V[5KU[=O7]I]#Q\^O%>O
M7HT;-RY1H@1_W3_\_?W3T]-Y'V!AB+W ;!D9&0L7+GSHH8?X]D-OOKZ^;[WU
MUJ9-F[!5 A""V MT$1,34[UZ=;[&Z &Q%P!  8'8"[3;L6/' P\\P%>70H5J
MU:HU>_;L\/!POD"NK*RLW;MW^_O[%RU:E"]9J%#CQHV3DI+X,F!5B+W 5,'!
MP8\__CC?;!C,S\]OP8(%&1D9?#0 D!_$7J"+5JU:\=5%)XB]   *",1>H-&I
M4Z><KRXJ7[[\-]]\H_ ).1$1$5V[=F45",US;#8;?S58$F(O,,_WWW_OO-$Q
MS>.//_[33S_Q,0& $\1>H-W2I4OYNJ(?Q%X   4$8B_0(CHZVOD&]C31E3K#
M2\;*E2N+%2O&2HT>/9J_#BP)L1>89,6*%3X^/FQ+8;[!@P?CFD< >8B]0*,K
M5ZX8^B,'8B\ @ ("L1>HEIV=W:1)$[:2].W;5_7!X*E3IQY[[#%6<//FS?QU
M8#V(O< ,@8&!18H48=L(=WGNN>=B8F+X$ '<)"HJZHQB-V[<X,L; +$7:#1D
MR!"^HN@*L1< @$'"PL+XY$/:K5NW^/)Z0^P%JJU;MT[W-20\/+Q<N7*.-:M6
MK9J6EL9?!Q:#V L,1\<G)MS 7DC-FC5II\X'"N .8\:,X2NHM)$C1_+E#8#8
M"[1(34TM4Z8,7U%TA=@+ , @;[[Y)M]"2=NT:1-?7F^(O4"=>_?NL>?J-&S8
MT#&?"@D)>4/:AQ]^N'CQXGP/&'?MVN7KZ^M8><Z<.?Q%8#&(O<!P_O[^CML%
MBZA<N;+U#YR@($#L!5YFU:I5?"W1F_6WWHB] ,!#(?8"[S!__GS'=:-LV;+7
MKEUS?,'1HT<=7Y"OHD6+?O[YY]G9V8X+DDF3)CF^C(HG)B:RUX"E(/8"8YT_
M?Y[%X=91OW[].W?N\!$#F NQ%WB9QHT;\[5$Q ,//%"^?/GBQ8O+W X2L1<
M@$$0>X%WJ%6KEN.Z\=577[$7*(F]\HP;-XXM:[/9ZM:MZ_B:I4N7LM> I2#V
M F-U[MS9<8M@-1]\\ $?,8"Y$'N!-TE+2RM<N#!?2UPI4Z8,K=N[=^\.#P^W
M_Z9*I4Z=.K5JU:J.'3N6*%'"\?76C[U&CQ[M.&"7$'L!@$58+?;JV[<O[U4:
M8B_($Q(2XKAB5*M6+2,C@[W&,?:J7KWZWG_0S';6K%D5*U9T*%#H_/GS;/'O
MOOO.\05OO_TV>P%8"F(O,%!Z>OJ##S[HN$6P(!-VV  R$'N!-SEV[!A?15QI
MU:K5S9LW>:%_NWOW[E=??56C1HV\1:P?>^%L+P#P4%:+O7"V%Z@P??ITQQ5C
M\N3)_!7_CKV>?OII]J\7+EPH5JR8_07#AP]G+\C,S/3S\[._H&C1HDE)2>PU
M8!V(O<! O_SRBWU;8%GERY<WX3$T %(0>X$W6;QX,5]%9+5NW9HFCKR*A*RL
MK NYE"_B+HB] ,!#(?8"+_#RRR\[KABAH:'\%:YB+_+BBR_:7]"R94O^SSDY
M??KTL;^ ;-FRA;\"+ .Q%QAHV+!ACML"RYHX<2(?.H!9$'N!-Q%ZADGITJ5C
M8V-Y":^ V L /!1B+_ "CN=AT?_F_YS+9>SE^%UHWKPY_^><G-6K5]M?0*9-
MF\9? 9:!V L,]/[[[SMN"Q2Z[[[[:-/36$*C1HWJUZ__Y)-//OKHHRKN().O
M4J5*X80O<!?$7N!-:!/-5Q%IHT:-XLM["]S;"P \%&(O\'3W[MUS?"I.BQ8M
M^"MRR<=>5,3Q]EX]>_9D+R!GSYZUOX ,&C2(OP(L [$7&.BEEUYRW!8H\?''
M'RN_+CH[.SLV-O;PX</SYLWKT*'#_???S\LIMGSY<EX=P!2(O<";L <GR3MX
M\"!?WEO@;"\ \%!6B[V"@H+6*O;[[[_SY:'@N7[]NN-:VJU;-_Z*7#*QE\UF
M&S1HD$.-0MNW;W=\09Z;-V\ZOH:.1ODKP#(0>X&!JE>O[K@M<*E9LV:\A(B$
MA(19LV85+UZ<UU7@U5=?Y>4 3('8"[Q)A0H5^"HBS>6=[#T7SO8"  ]EM=@+
M0-2)$R<<U]+^_?OS5^1RC+W\_/Q&_V/8L&'UZ]=W*%#HF6>>L=EL?/G<1TX[
MO@R'DU:&V L,].BCCSIN"USZ]==?>0EQH:&A=>K4X:5=\?'QB8^/Y[4 C(?8
M"[R)XV./Y-%6-]])I'? V5X X*$0>X&GHX-!Q[4TW^L3<_X=>\EXY)%'PL+"
M^,*Y;M^^[?C*?&][#Q:!V L,)!I[14='\Q*J7+ITJ63)DKRZ*[MV[>*% (R'
MV N\QKU[]_CZ(>V^^^[CRWL1Q%X X*$0>X&G8VE4^_;M^2MR*8F]_/S\8F)B
M^)+_" \/=WQQKUZ]^"O ,A![@8%$8R\Z9.(EU)H_?SZO[LJ4*5-X%0#C(?8"
MKQ$7%\?7#VF(O1PA]@( BT#L!5[ \=SS.G7J\'_.Y1A[5:Q8<?8_IDZ=2E,4
M^S\=.'" +_F/7;MVV5]&QHT;QU\!EH'8"PQ4J5(EQVV!2SK&7C=OWA1]SJ,U
M$_J(B(@M6[9,F#"A?__^G3IU:M&B1<.&#:6N4=?N^O7KV[=OGSY]^L<??_SZ
MZZ\___SSM6O7KEZ]^C/////JJZ^V;MVZ9\^>\^?/#P@(L/*S+Z.BHF@7M7+E
M2CKR[-*E2ZM6K6CP#1HTJ%FS9HT:->B]-&G2Y.VWW^[8L6/?OGWGS9M'.ZWP
M\/#L[&Q>R!1>'WO=O7N75I@9,V8,&C2(UF%:KYYZZJG''W_\E5=>^>"##P8/
M'DS_1#,/+[[>32\7+EQ8O7HU;0T^_/!#6J6???;96K5J5:U:E>9S]"=KUJQ9
M]^[=ITR9LG'C1JFS\8T6$Q/#UP]IWAU[>=.]O6A_^MUWWTV<.+%/GSYMV[9]
MX847:$-*J]\[[[S3HT</>J=???45[:KX8A[HQHT;Z]>O'S]^_">??-*F39M&
MC1K1.Z5];LN6+?W]_6E;_?777]-K^&)61;O"K5NWT@:V=^_>S9LWIZT$;2MH
MBT';#=HATA:8=H)CQXZE-W7RY,FLK"R^/.B$9A?7KEW[]==?%RQ80+N\CS[Z
MB-:HEUYZB>975:I4H3\'?9N:-FWZ[KOO=N[<><B0(<N6+:,YC!MO?8C82QTZ
MBCERY C]^4:-&M6^??N77WZY7KUZM VI5JT:37M>?/'%M]YZJU^_?G/GSMVY
M<V="0@)?WF/1]I\F)__][W]I4T-3[N>>>X[>-6UPZ'_3L15M9.A?S5^?:0SV
MM=37U_?.G3O\%3DY]/>ROX;=TIZ.=^S_1']*QW]R1),N^\O(DB5+^"O ,A![
M@8'<>+87H2D=[T"6U!FPREV]>K6_8K2IY<O_(S@X^////Z<YM^-S<QV]__[[
M?!EM @,#APT;]N233_*>9-'KZ4 H)"2$ES-=;&PLS2'H6*5%BQ:E2Y?F U6F
M1(D2- VE@\_3IT_S#G1R[MPYOA[T[T_S73X4:?7KU^?+R]J]>S<?A +:8R^:
MY=.L_;///J./M$B1(GR9_%2H4($F&=NW;\_(R.#E"K#DY.2U:]?25_ZAAQ[B
M'YFLRI4K=^W:E3Y/?;>KCK[\\DNVOO7HT8./0YJ/CP];7-Z<.7/X""S,C;%7
M='0T_^RD[=V[ER^?*RTM;=NV;0,'#JQ;MRX?JP0ZKJ.OO,RN37=A86'\_4B3
M>KY;2DK*=]]]U[=OWR>>>(*_)0D-&C08-V[<B1,G>"T+L-EL>_;L^?333Q]_
M_'$^;EFE2I5JV;+ETJ5+#;K/Z=:M6_F?1-;Z]>MY"9U,FS:-=R8A("" +ZQ8
M1$3$IDV;:&;UXHLO*K_C(5.N7+DWWWQSP8(%-+WD'>CDYY]_YF^[?W_:??"A
M2*,1\N5E7;ITB0_"E0T;-O JTG[YY1>^O,$B(R-GSY[]^NNO/_#  _S3D49[
MP'KUZ@T=.O38L6.\HL'RG8M*.7/F#%\^5U)2TKIUZWKW[NV8+LF@]]NH4:-)
MDR:=/7N6US(&;08=!T!K$7^%;.P5'AY>M&A1^[_NV+'#\5_MGGON.?MKR(4+
M%_@KP#(0>X&!W!M[??311[P#6<V;-^<E!-&LFA>5MG+E2K8X[8?&CQ]?JU8M
M_E(G>L5>M-.B U?1M,L9'>W0V\G,S.0=&(D&3SNAP8,'*S\J4X[F?/WZ]3M\
M^##O59N??OJ)]V0PFHKQ02B@)?:B ]&)$R>*/L75$1VM;=Z\V;%FP73JU"G:
MB*E[-*VCLF7+TLSURI4KO /-WGCC#=Z9D61^;K4@-\9>-.WFU:5]\<47;'$Z
M!NO;MV^9,F7X2Q6CPS]S#N1H$\W[EO;--]\X+IN=G1T8&-BS9\\''WR0OU2Q
M=]]]5^J8T'S1T='_^<]_'GGD$3Y*046*%&G3ILW^_?MY!]KLW;N7]R2+CJ5Y
M"3W0I^3KZ\L[DR :T%#QM6O7]NC10R@V4H@F6F/&C/GSSS]YK]K0EH?W9#"9
MZ\6DT!:)5Y'V^>>?\^6-0=N0[[___K777O/Q\>&#$%2S9LT9,V;0M);W80RA
MN>CV[=L=E\T+UKMV[2J4\3$=.G0P(1YB;[-5JU;\%;*Q%QDX<*#COSI?E'#Q
MXD7["P@=P;$7@*4@]@(#N3?V&CER).] %LU?>0E!ZF*OU-34Q8L7"V5/VF.O
MC(R,18L6^?GY\=(:T.9^_?KUSGL%(VS=NM7QJGOC-&_>7,4438K05$,79L9>
MNW?O;M:LF?;Y7YX77GCAX,&#_QY701$4%/3..^_P3T0;^K[0//7RY<N\,PT0
M>\EPX[V]U,5>*2DI\^?/5_$<9"GMV[?7_1"=41=[W;Y]>^;,F0K/4'")MGA=
MNG0)#P__U\C,%145U;]___OOOY\/3AOZQM'Q+>],+9H;B-[XXN3)D[R*9@L7
M+N3=2'CQQ1?YPK(F3)C 2Q@@;TL>&AK*NU?+(V*O?OWZ\2K2S(F]UJU;I^/6
M,D^9,F5H+<KW6CQ]"<U%[;%7?'P\K2U5JE3AKU"%UN2>/7L:>LUX6EI:B1(E
M[#W2MCHX.)B]QO'>7LZQ%VU:'=.]-6O6L!=T[][=_J]DU*A1[ 5@*8B]P$#N
MC;U&C!C!.Y!%,U=>0I!H['7SYDW:PY4O7Y[_FRL:8R\Z5%!R3IDZ39HTN7[]
M.N]2;W0 PSLV4M.F30\=.L0'(4YHJJ$+<V*O7W_]M7'CQOP?-//U]9T[=RX?
MG%>[=>L6S>_UB@Z=%2M6;,J4*7IM:1%[R?"@V"LN+F[BQ(GERI7C_Z99R9(E
M::/'QZ<?T=B+CF%&CQY=JE0I_F^:T7Y<RP5QJMELMH4+%QKQCNPZ=^Y,GQOO
M6!71'R/I2\1+:*9\5[5HT2*^L*Q!@P;Q$H:AG2/]741/1LL78B]1(2$A-"?D
MO>J'#IVV;MW*>]65T%QT^_;M$1$10X8,T7[NN;-''GDD*"B(CT\_[+J?YLV;
ML]_FY6,O,FK4*/L+'GOL,<?ITXD3)]@/\-:\\AWL$'N!@=P;>W7JU(EW(&OH
MT*&\A""AV*M!@P:J;_>@.O;*RLJ:-&F2T>=)T>$3.RE:=R;'7H5R9YG3IDW3
M>-M[H:F&+DR(O42_YJ(^_?13DZ^?=1<Z;'[XX8?Y^S< S>UT.0T'L9<,3XF]
MZM6KI^5:%9=HR^E\':5>A&(OVN?J?CZ4HR)%BJQ8L8(/T4B1D9'TI>#C,$#I
MTJ5UV:>?/GV:EY:E^W6.=/2N\$>%PH4+Q\7%\>5EF1E[Y2E9LN3WWW_/QR$(
ML9<0VIHIO%VI1IT[=TY.3N;=ZT1H+MJP84/11X0)H4.AC1LW\B'JA*8Z;/ 3
M)TYT? 'M+M_]1__\'A=&VX%6K5K97Q,8&)CWWQ,2$JI5J^98N5V[=O]>%"P'
ML1<82/1X6-_8ZZ677N(=R-(^816*O;10%WO=N7/'S,-4'8_BG)D?>^5IV[;M
M[=NW^6@4$YIJZ,*$V,L$M-ZFI:7Q47H7^DL9G4<[*E6JU+9MV_@@!)FY/2F$
MV$LQH=C+'(,&#>*CU(-0[&6.\>/'\U$:8]^^?:*/N=#"Q\=G[-BQVF]B('HO
M3GVO<YPS9P[O0$+KUJWYPJZ8'WOE^>RSS[0\A1.QET+)R<D=.W;DG1F)OBP7
M+U[DX]"#^7-1EXQ[9 U;>6A3IOVA![0E9'>BH/F;"7<K XT0>X&!W!A[W;AQ
M0_084OLM>*T<>\7&QK*GC9A@ZM2I?!PZ<5?L52CW%F:JGZGT\\\_\W(&\X[8
MB_3LV9./TEMD9V</&#" OV'CT>1O^?+E?#0B$'O)0.S%:%S9\F7!V(MLVK2)
M#U1OFS=O-N>4$^;##S_4>.[MM&G3>%%9HT>/YB4T4#X+4O%'=%?L52CW(1(I
M*2E\0,I,F3*%ES.8)\9>B8F)C1HUXCT9KURY<J=.G>*CT<S\N:A+OKZ^VM.P
M4PTQ   U'DE$052H?,7$Q+#GEM"GJB5/M]EL0X<.=2Q8*/>Z!/XZL![$7F @
M-\9>4Z=.Y=5EE2E3)B,C@U<19-G8*SX^OG;MVKR**6;-FL5'HP<WQEZD?OWZ
M=^_>Y6-2P/Q?V+PF]BIDS&&SV]'\J7?OWORMFL7'QV?APH5\3(HA]I*!V(LI
M6K2H[O=PL6;L5:)$B?/GS_.QZF?MVK6BO^KIJ$.'#EHF2]>N7>,59>EXG>/E
MRY=Y=0FE2I52L8MW8^Q5*#>1Y -2!F=[N107%]>@00/>C5GH\$3W+:?Y<U$E
MRI8MJ_I'97G???<=Z^O^^^__ZJNO^.L4H)6A18L6K%K=NG5->PHG:('8"PSD
MKMB+9IRBCR3OVK4KKR+.FK%7>GKZ*Z^\PDN8R(A;&KLW]B+=NW?G8U+ _%_8
MO"GV,N*PV>W,_Z6=\?'QH=62#TL9Q%XR$'LYJU*E2GQ\/!^N!M:,O<@33SQA
MT./8Z"T;>I\=)88/'\Z')4)T0J+77:(___QS7EJ"NI.+W1M[D04+%O Q*6#^
M/LBS8J^LK*QFS9KQ/LQ5H4(%O1XKD<?\N:A"SS[[+!VS\.'J(=\'K?K[^PN=
M)GGTZ%'G!UF6*U?NRI4K_*5@28B]P$!NB;TN7[[\^../\]*NZ!+-6#/V8L\Q
M,1_ML&-B8OBPM'%[[$66+EW*A^6*^;^P>5/L52CWIM0:GRI@*33[=^-9&W9^
M?GY__?47'YP"B+UD(/;*UX@1(_AP-;!L[%5(US^H77Q\?.7*E7E/[O#CCS_R
MP2FV?/ER7DZ67M<Y/OWTT[RTA/W[]_.%%7![[%6D2!'Z1O!AN8*SO>3E&Y>8
M[_777]=^9ST[\^>BRJE+;UVBJ6.'#AUX9X4*5:Q8<=Z\>;=NW>(+_-NI4Z<Z
M=NSH_$ ,^M+MV[>/OQJL"K$7&,CDV.ONW;N+%BTJ4:($K^L*'4OS6JI8,/9:
MLV8-7]@=6K9LR4>FC15BKZ)%BX:%A?&1R3)_JN%EL5>AW&=I\^%ZIILW;S[R
MR"/\[;E)TZ9-5=P4&;&7#,1>^2I>O#BM^7S$:EDY]BI;MJR^E[W08=N[[[[+
MNW&3<N7*7;]^G0]1F82$!-I[\HK2'GOL,5Y"W/GSYWE="94K5U:7+[@]]B)5
MJU85/5D&L9>,/7OV^/KZ\@[<9/+DR7Q\:ID_%U6.CAQ%UV&%,C(RI%8DVB*U
M:=.&)LST%Z=M161D)$WO3YX\N6'#AI$C1TK=)<;/ST_%R@QNA-@+#&1"[$5;
ML6O7KFW:M*E___YERI3A%971ZT#::K%73$P,S4WYPFZB[_.)K1![D5Z]>O&1
MR3)_JN%]L5?]^O6]X(0O.JQZZZVW^'MS*Q5/H$/L)0.QEY3//ON,CU@M*\=>
M9-JT:7S$&LR:-8MWX%9-FC11?7O[MFW;\G*RM%_G2-LW7E2"ZI/+K!![D25+
MEO"1R<)%CE*BHZ,K5JS(J[N/KZ]O0$  'Z4JYL]%A8BNPT*HN"[7B3_]]-,&
MW8D,C(/8"PQ4J5(EOIV0]>:;;[[M"ATKMFC1HE&C1C5JU"A5JA0O(4[U?4"=
MZ15[%2U:]*FGGNK0H0/-HF@&-F;,&']__]=??_V!!Q[(>X'"V*MKUZ[_+JR4
MCX_/\\\_/VG2I T;-NS?O__LV;.TKZ7_/6'"!/KOSF?Y*E&G3AUUOZ#F2TGL
M]>BCC]+:,G3HT*E3IRY>O'C=NG4[=^[<MFW;RI4KQXX=^]Y[[VF?T-"^\\:-
M&WQPTLR?:E@D]BI=NC2M +0.=^[<N77KUE2_>/'B_$6*T1^1C]C3S)PYD[\K
M0;5JU:(-9J]>O4:.'/G11Q^]^NJK&M=GFE*+'HT@]I)!FV[^!F3I&'N%A(3P
MZE92HD2)A(0$/FA5+!Y[E2]?7NC&,3*"@H(T'JK1]J%ITZ:TK: M!FTW:.M!
MVQ#^(D$T)> #5<;Y#M/RM$>ERN]]<>[<.;ZP,BYC+]K&UJQ9LUV[=O1V9LR8
ML6S9LHT;-]*L8,N6+?2_AP\?3E-<[=/:JE6K"OTRY!%G>_7MVY=7D:97[*5Q
M!T=?V 8-&K1ITV; @ $T$:5Y^PLOO*#B>A1'=%25F)C(!RK._+FHD"I5JJB.
MU)4X=.A0PX8->:^*T3$:_4&3DY-Y7; \Q%Y@(-&SO<Q',R$=+T/0&'L]_/##
MGWSRR8\__BCU""'Z[[_]]AO-%X\<.<+_S<F9,V=4Y%/WW7<?32_D+UZ(B(CH
MV;.GBA._UZY=RVNIE6_L5:1($9K63YTZE79I+B_4SQ,:&CISYLRZ=>OR6HK-
MFS>/%Y5VY<J5F4Y>>^TU7E0:O<'9(HX?/\X'H8 NL=>33SY)LSV:T,?&QO(.
M<E?F'W[XH7'CQGPQ!=Y[[SU>SJ/0!R+ZS T[VJB.&S?NPH4+O&CN&63[]NWS
M]_>WY^.BGGON.:'C)=H6L?5-Z#8HM(%BB\M;MVX='X&%>4?L1>M;CQX]5JY<
M2;N><^?.Q<?'T]%(5%04;5BF39M6OWY]OH R:]:LX8-61<?8JWKUZKU[]UZU
M:E7>12YT;)GW3H\=.T9_&M7[""WWP'(D>AMXN^+%B],V@;8,^?[L1%N2L6/'
MBOY":5>L6#%UMP5,2TL3RG?HK\-+B#AY\B2O*(%6:;ZP8OG&7B5*E&C=NO7"
MA0M/G3HE-;5SE)6515^NSS[[3/4?A00&!O*ZTNA+Q"<E,V<J3PD+Y3X2BF^L
M9<G/,/-E?NRU8\<.7E<QVI,N6K0H+BZ.%\W)24E)H9FPEG.]QXP9PXN*TS'V
MHE6E7[]^JU>OWKMW+VU/;M^^G9&1$1D92>L5S56$5B1'!P\>Y(/6%4UU-FS8
M4*-&#=ZQ+)JT?/CAASC)RW,A]@(#:=EMFZ!V[=HJ]KXRU,5>-"L=.'!@4%"0
MT &G2ZU:M>(]N4(S>SI>XH4DG#AQ0O3.1+5JU<IWYJV"8^Q5M&C1+EVZT!Q%
MRY.S#APXH"Z">?'%%WDM032)X46EC1PYDB]O "VQ5^7*E2=.G!@>'LZ+YH?6
M^25+EHA&J'2\9.@O@48;.G0H?TL*T'QKP( !2GY@O'SY\JNOOLJ75V;+EBV\
MG(B8F!A>4=I]]]W'E_<B;HR]M%_D^.RSS]*!>FAH*"_MY-MOORU?OCQ?WI6/
M/_Z8%U)%>^SUTDLO+5NVS.5SN&C/M7SY\I(E2_+E71DT:!"O)4[U,6K3IDU=
MOC5"6Y7^_?NK^)V,].G3AY=3QM_?G]>2I>XGG#R???89+R=ASIPY?&'%'&.O
M,F7*T/\-" A0<>^./+3*;=RX45UJ0'L*7D[0FV^^R8M*V[1I$U]>;R;'7O3A
M*W\ @B/:1-"&@I?+SZY=N]0]GH(.&;0_U5'U)L7NM==>6[ERI<N9'DW5YLZ=
MJ^+L?A5W75"!OI[;MV^G;9&?GQ\?@8.\*V!HO<KW%T?P((B]P$!6CKV:-&F2
M[TDH6HC&7K0GH"V[7I=[.+ITZ1+OS)7FS9LK/$/*+B(B0O0JB3U[]O JJJQ;
MMXZF%[5KUYX]>[:.?\>U:]>*GBE#A^ZIJ:F\D BOB;UHHOSSSS^KN#/ZZM6K
M>2U7C/XET#@Q,3%"MW/.0VO[WKU[>2UIV=G9TZ9-XU44J%>O'J\E K&7G2?&
M7L6*%>O1H\>Q8\=X15DA(2$//?00KR7KD4<>X55441U[E2A1HD^?/L'!P;RB
MK./'CXO>+I-V4KR*N$:-&O&Z"DR?/EWHMS3:.ZO(]0H7+AP9&<EK*4 ;-%Y+
MENKK'.E#J%JU*B^7'U]?7Z&[%C"C1HVB#_"EEUY:M6J5QEF!769FYH0)$T03
MR:>??IH7$E3 8Z_-FS?SH@H\\\PS+F,@1[=OWV[3I@VOHH#VY^&JCKU*ERX]
M>/!@Y3^0YPD("!!-OK3_HBR$)JZ'#AU:L6+%E"E3!@P8\/[[[W?KUHVV.5]\
M\<7&C1O5G=,*%H38"PQDS8L<_?S\5JY<*30=5$@H]JI0H8)Q6]*Q8\?R_F31
M)$G=+.WLV;-TI,3+2:-C*E["8NA B/XT?-RR5#PRW)$7Q%XTV_OMM]]X%1&B
M]Z$;-VX<+^$A5*11]!53<3,40K-_7DL!FOSQ0HHA]K+SK%O:TP$_'5BJ_@GA
MR)$CHD?FJN^@Y$A%[%6D2)'APX>+_L9CI^)P4>-)Y2=.G. 5%5!WY$]'IT([
M]#P3)T[DA12PV6Q"OXRJOLZ15DY>2T*+%BWXPM:P=>M6H3N[T:95XTWEK!9[
MF7Q+^V;-FO&BKM2J58MV?[R0*^GIZ;36\5JNE"M7+BTMC=<2\?///_.BKM"6
M@>9=2LXWS]>&#1MX15FT#JO>2@-(0>P%!K)4[$73^N;-FZ]<N5+'FWDQ0K'7
MXX\_SI?72596EM!LLF3)DI<N7>)5%)LW;QZO*(WZTKBW-L$OO_PB= BW=.E2
M7D*$I\=>DR9-TG[M:E14%!V.\M+27GOM-5["$] '5:U:-?YF9-&JJ.7V0(,'
M#^857>G:M2NOHAAB+SL/.MN+CO'.G#G#JPCZY)-/>%U9*U:LX"7$B<9>+5NV
MO'CQ(J\BZ(,//N!U96W>O)F7$-&S9T]>T94A0X;P*HKMV+%#:/=7*/<VV^JN
M.J?=&:\E2]UUCLJW@:M7K^8+6\;4J5/Y<&4%!07Q$B*L%GN9>;:7Z/:S4.[S
M(H3.\W*4DI+RW'//\8JN?/OMM[R0"-'XOD.'#MIO:"4:\.W>O9N7 - &L1<8
MR%*QEY^?'\T% P,#M1^B2[%([/7++[_PSF1IG"*DIZ<+W>1+XVE!YNC2I0L?
MM[1)DR;QY45X>NQ%ZQM?7I5V[=KQTM)TN73(?/OV[>/OQ!5_?W]>141:6IKH
M35N+%2NF^DP!Q%YVGG*V%^T9^?*J"'5:2/-^)X]0[%6K5BV^O"I'CQ[EI64M
M6K2(EU",OK^BCWZK6;.FQM^6>O3HP8NZLFO7+EY%@>#@8%Y(UJA1HW@)5VB^
MIW!^4KQX<=5GLIB WDB=.G7XH*5I^;$DQWJQEYEG>PE-R?)H?-S*F3-G:&_(
MB\IJWKPYKR)"Z&RO1HT:\>55$3TVT?$I6 !Y$'N!@2P5>]D]_/##M%.\??LV
M'ZYF%HF].G;LR#N3]M!##VF?ZLV<.9/7E:;]K@0F$#H?NW___GQY$4)S+"^.
MO;[]]EM>6EJ9,F7X\IY ]&;V9<N657W=F9W0!#?/]NW;>15E$'O9>4KL1;L
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MV#"A,](-@MB++Z_6PP\_S*M+\ZS8BXZL^!N0I6,(8M>D21/>C;0:-6KPY15
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MC^9O6!9B+Q4*0NQ%Z+"3%U5@VK1IM/'GM:31AREZ4^U"N=_BJU>O\EHZ$;U
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M)R8F]O;VX@XH8+&7'HN]#&.Q%W'P[<O+RUN]>C4>@9'@BQD2$O+@P0/<@01
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CK*P,ZK2O7[_B[1F&H>E_6F4$#6\&B#@     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139652300202176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Verona Pharma plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1489389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3 More London Riverside<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SE1 2RE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">283 4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.05 per share*<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001657312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>vrna-20230509_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vrna-20230509.xsd" xlink:type="simple"/>
    <context id="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY180L2ZyYWc6OTY3NDU5OWFhMDNjNDQ2MThlY2I0ZmI2MTdiMmM1NjgvdGFibGU6MzQ0MDMyOGE1M2M2NDQzZTgxNDhkYTdjNmFkN2FhMjMvdGFibGVyYW5nZTozNDQwMzI4YTUzYzY0NDNlODE0OGRhN2M2YWQ3YWEyM18wLTEtMS0xLTgwNTg5_fdd5fe7c-9cb9-4fb3-962c-ce8e155498bc">0001657312</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY180L2ZyYWc6OTY3NDU5OWFhMDNjNDQ2MThlY2I0ZmI2MTdiMmM1NjgvdGFibGU6MzQ0MDMyOGE1M2M2NDQzZTgxNDhkYTdjNmFkN2FhMjMvdGFibGVyYW5nZTozNDQwMzI4YTUzYzY0NDNlODE0OGRhN2M2YWQ3YWEyM18xLTEtMS0xLTgwNTg5_9b315bb9-7b75-4b14-821a-6a9058f93bc1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjIz_9f34f9e3-a5eb-4de5-891b-067e3cb3a98f">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8yNDA_241f75e1-4e59-48fd-a170-263ecbcf939e">2023-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjE5_6cba8165-2591-4743-98be-9e2b02b5d188">Verona Pharma plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6NTkyOWI2ZDRmOThkNGM3OWIwODE2NzVmY2ZlNWNlNTEvdGFibGVyYW5nZTo1OTI5YjZkNGY5OGQ0Yzc5YjA4MTY3NWZjZmU1Y2U1MV8wLTAtMS0xLTgwNTg5_36cae265-8142-4d80-80e1-42ef12c27997">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6NTkyOWI2ZDRmOThkNGM3OWIwODE2NzVmY2ZlNWNlNTEvdGFibGVyYW5nZTo1OTI5YjZkNGY5OGQ0Yzc5YjA4MTY3NWZjZmU1Y2U1MV8wLTItMS0xLTgwNTg5_e03b2fa2-1481-4d39-8640-188ea7eab964">001-39067</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6NTkyOWI2ZDRmOThkNGM3OWIwODE2NzVmY2ZlNWNlNTEvdGFibGVyYW5nZTo1OTI5YjZkNGY5OGQ0Yzc5YjA4MTY3NWZjZmU1Y2U1MV8wLTQtMS0xLTgwNTg5_e8506cbf-4c1e-4615-80ac-bd8a47d9f5a9">98-1489389</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjI0_7e93d31e-3648-4bf8-8e3f-04af62952ab0">3 More London Riverside</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjI1_15c27cde-e5d1-4bf1-81ea-d3537bda1fc0">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjIw_82bd4543-1b99-416e-bf46-e3647f55c1bf">SE1 2RE</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjIx_c194cbad-fdcf-419d-a7e9-8ad132900b21">GB</dei:EntityAddressCountry>
    <dei:CountryRegion
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjE2_a1d3bdd9-9157-48de-bbba-e904dd679cc0">44</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjE3_2a4118a0-f3e3-44e2-9113-198a67a62bb0">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjIy_fc7f5bc0-989a-413c-aa0a-f6295feba2ac">283 4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6ZmZjMDU5MDQ4OWNiNDEyOWE3NjNjMzMxNmM1NDM3ZjUvdGFibGVyYW5nZTpmZmMwNTkwNDg5Y2I0MTI5YTc2M2MzMzE2YzU0MzdmNV8wLTEtMS0xLTgwNTg5_4e79c6cb-6cad-4776-bd2f-7fb0287f028c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6MmQ1YjYxYTY2NzJiNDZlZDk1NTQ3MzNhM2NiOWU1M2EvdGFibGVyYW5nZToyZDViNjFhNjY3MmI0NmVkOTU1NDczM2EzY2I5ZTUzYV8wLTEtMS0xLTgwNTg5_98e6ee5c-b9e9-4bf5-aeef-bc4f0b175383">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6YTZlZWNmNDYxODFlNDk1MDkzNmFhNmRhZmI1N2Y0MjMvdGFibGVyYW5nZTphNmVlY2Y0NjE4MWU0OTUwOTM2YWE2ZGFmYjU3ZjQyM18wLTEtMS0xLTgwNTg5_bf5a0f0f-8130-467b-8c4a-ce544fcc3698">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6MGUwZDVjZDM3MWI4NDI1OGFhZGE0ZmQzNjEwNzdkMWMvdGFibGVyYW5nZTowZTBkNWNkMzcxYjg0MjU4YWFkYTRmZDM2MTA3N2QxY18wLTEtMS0xLTgwNTg5_9ea1823a-23fd-49ff-89b6-ef9b21f6e0b1">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6ZmMwYWI0OWFjYWQ3NDQ3ZTliYjRmNTU2MmFkZGNiOTAvdGFibGVyYW5nZTpmYzBhYjQ5YWNhZDc0NDdlOWJiNGY1NTYyYWRkY2I5MF8xLTAtMS0xLTgwNTg5_0356b6f9-7ee1-44bd-ba64-0d74becbde90">Ordinary shares, nominal value &#xa3;0.05 per share*</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6ZmMwYWI0OWFjYWQ3NDQ3ZTliYjRmNTU2MmFkZGNiOTAvdGFibGVyYW5nZTpmYzBhYjQ5YWNhZDc0NDdlOWJiNGY1NTYyYWRkY2I5MF8xLTEtMS0xLTgwNTg5_c42609b1-8d26-48df-aa12-5647b83cab07">VRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGFibGU6ZmMwYWI0OWFjYWQ3NDQ3ZTliYjRmNTU2MmFkZGNiOTAvdGFibGVyYW5nZTpmYzBhYjQ5YWNhZDc0NDdlOWJiNGY1NTYyYWRkY2I5MF8xLTItMS0xLTgwNTg5_8f1d0fbd-5ac8-49a2-b970-220967423686">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMmRjMDQzMGYzNjQ2MDI4ZjQ1N2Y4MzM0YTFjMGNjL3NlYzoxZTJkYzA0MzBmMzY0NjAyOGY0NTdmODMzNGExYzBjY18xL2ZyYWc6MzM5Y2I5ZmI3ODI1NDBkZjg1NWNlNDlmNjIzYmM5NjQvdGV4dHJlZ2lvbjozMzljYjlmYjc4MjU0MGRmODU1Y2U0OWY2MjNiYzk2NF8xNjE4_74a8bb47-b090-46d8-a9ef-02d7d30eca7f">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,)M@=.6*X*.&_OVX[>=I)16N]/$& RJ7 !\W\:-16)/[-@,'#ER@V<0XRE7
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M.@T_P,C*52# #7P$<S7*Y^M=3->5/+C V4%R3TZU]A^"1VK3HDG,5B#D775
M5^T/W?N&D6E^T%U* \?F_';#*)B'?0&^7TEIC@U[=B[^^AC^#U!+ P04
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "M,:E6!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( *TQJ58/E^]Q[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *TQJ5:97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MK3&I5J3^LYI=!   !A$  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *TQJ5:?H!OPL0(  .(,   -
M          "  : ,  !X;"]S='EL97,N>&UL4$L! A0#%     @ K3&I5I>*
MNQS     $P(   L              ( !? \  %]R96QS+RYR96QS4$L! A0#
M%     @ K3&I5JK$(A8S 0  (@(   \              ( !91   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( *TQJ58D'INBK0   /@!   :
M      "  <41  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( *TQJ59ED'F2&0$  ,\#   3              "  :H2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /03      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="vrna-20230509.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="vrna-20230509.htm">vrna-20230509.htm</File>
    <File>vrna-20230509.xsd</File>
    <File>vrna-20230509_lab.xml</File>
    <File>vrna-20230509_pre.xml</File>
    <File>vrnaq12023pressrelease.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vrna-20230509.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "vrna-20230509.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vrna-20230509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vrna-20230509_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vrna-20230509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "vrna",
   "nsuri": "http://veronapharma.com/20230509",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230509.htm",
      "contextRef": "i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://veronapharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230509.htm",
      "contextRef": "i6515e3d64c6348179a873c1e28d5d8eb_D20230509-20230509",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region",
        "terseLabel": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001657312-23-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001657312-23-000008-xbrl.zip
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MY^K5Z8OU;[+E=\V?OO@?4$L#!!0    ( *TQJ5:VL4':TP8  +HR   5
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M6>N7\Q$W*K>6;L\I;V]EK=XMJ_)A<ZR88UE.80N-G-8K1+!26S IX]H::?7
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M-P5Y-,/,'!H4K2^V@-ZC0@NX'K"@5PU3'5]>Y$R5<EI7Y('$)*UA]9MVM\6
MGHE<]"K9G#TW$[U H@#.I&#=D4TW&,5A%BG,DSP,0P^-M](&]>::%MUBOME
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M0>A.X9]QZGMO_Q]02P$"% ,4    " "M,:E66&,U/&86  "ON0  $0
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%2      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
